<DOC>
	<DOCNO>NCT02479750</DOCNO>
	<brief_summary>This study evaluate performance ColdZyme® mouth spray prevention common cold symptom experimentally induce rhinovirus upper respiratory tract infection healthy volunteer . Half participant receive ColdZyme® mouth spray half receive placebo .</brief_summary>
	<brief_title>Evaluation ColdZyme® Experimentally Induced Common Cold .</brief_title>
	<detailed_description>88 subject inoculate rhinovirus 16 via nasal route . The subject randomize 1:1 ColdZyme® placebo . Treatment ( 6 dos per day ) apply 11 day day inoculation . The subject visit investigational clinic 6 occasion . During visit subject leave nasal ( lavage ) pharyngeal ( swab ) sample quantification virus replication . All subject diary score cold symptom .</detailed_description>
	<mesh_term>Common Cold</mesh_term>
	<criteria>Healthy male female subject 1670 year . The investigator judge definition healthy detailed medical history physical examination . Females childbearing potential : shall use reliable method birth control . Reliable method hormonal contraceptive ( combination pill , injection implant ) , intrauterine device , condom declare absence sexual contact . Postmenopausal woman define absence menstrual discharge least two year . Signed informed consent form prior studyrelated procedure . Willingness ability adhere prohibition restriction specify protocol . Perceived least one cold per year Smoker , last 12 month Any cold symptom within last month sore throat , sneeze , rhinorrhoea , malaise , nasal obstruction cough . Presence ( screen ) serum rhinovirus 16 neutralise antibody titer great equal one two dilution . Active allergic rhinitis , asthma chronic obstructive pulmonary disease study period . Nasal disease , e.g . nasal polyposis , significant septal deviation , chronic rhinosinusitis , etc . Females : Pregnant , breastfeed intention become pregnant study . Evidence history drug alcohol abuse . Use prescribed nonprescribed medication ( except contraceptive , paracetamol ibuprofen ) within 2 week prior first administration investigational product . Use counter cold prophylaxis product ColdZyme® , Cvitamins , zinc Echinacea within 1 month prior first administration investigational product . Participation clinical trial medical investigational product within 60 day prior first administration investigational product . Hypersensitivity/allergy device ingredient Individuals close contact risk patient group : infant ( less 6 month ) ; extremely elderly infirm ; pregnant woman ; patient severe lung disease ( asthma/cystic fibrosis ( CF ) /COPD ) ; patient immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>